Navigation Links
US CNS Disorders Drug Pipeline Insight 2014
Date:8/29/2014

DUBLIN, Aug. 29, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "US CNS Disorders Drug Pipeline Insight 2014" report to their offering.

The Central Nervous System (CNS) disorders market in US is one of the largest segments of pharmaceuticals industry. The numbers of CNS disorders have increased at an alarming rate, while the available therapies were unable to meet the market requirements. There has been steady to rapid growth in the market for CNS disorder, especially over the past two decades. The market for CNS therapies is one of the largest therapeutic categories and also one of the fastest growing. US account for more than 55% of the global CNS Disorders drugs market.

Within the CNS market, the biggest therapeutic area is the market for anti-psychotics, followed by anti-depressive and mood stab markets. Anti-epileptic and anti-Alzheimer's markets come next while other classes of drugs have a marginal share. Antipsychotics have a market share of nearly 30% while antidepressants corner about 25% of the market. Anti convulsants have about 17% of the market share while drugs used in Alzheimer's Disease form about 9% of the market, with ADHD and narcolepsy drugs medications have about 7% market share. The other classes of drugs have market shares of less than 5% each.

Key Topics Covered:

1. Introduction to Central Nervous System (CNS) Disorder

2. US Central Nervous System (CNS) Disorder Market Overview

3. US Central Nervous System (CNS) Disorder Incidence by Disease

4. US Central Nervous System (CNS) Disorder Market Dynamics

5. US Multiple CNS Disorder Drug Pipeline by Phase & Company

6. US Alzheimer's Disease Drug Pipeline by Phase & Company

7. US Multiple Sclerosis Drug Pipeline by Phase & Company

8. US Parkinson's Disease Drug Pipeline by Phase & Company

9. US CNS Disorder/Neurodegenerative Disorders Drug Pipeline by Phase & Company

10. US Epilepsy Drug Pipeline by Phase & Company

11. US Migraine Drug Pipeline by Phase & Company

12. US Huntington's Disease Drug Pipeline by Phase & Company

13. US Neuropathic Pain Clinical Pipeline by Phase & Company

14. US Schizophrenia Clinical Trial Insight by Phase & Company

15. US Sleep Disorders Drug Pipeline by Phase & Company

16. Competitive Landscape

Companies Mentioned:

  • Alkermes
  • Allergan
  • AstraZeneca
  • Biogen Idec
  • Bristol-Myers Squibb
  • Eli Lilly
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • Sanofi
  • Sunovion Pharmaceuticals
  • Teva Pharmaceutical

For more information visit http://www.researchandmarkets.com/research/vtvc8r/us_cns_disorders

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net


'/>"/>
SOURCE Research and Markets
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
2. Blood Disorders: European Hematologists Gather in Amsterdam, June 14-17, 2012
3. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
4. Elsevier and the Society for Vascular Surgery Announce Forthcoming Launch of Journal of Vascular Surgery: Venous and Lymphatic Disorders
5. Global Anxiety Disorders Industry
6. Soligenix Announces Issuance of US Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
7. Global Market for Neurodegenerative Disorder Treatments to Reach $23.5 billion in 2017, Weakness Disorders Treatments Outpace Progressive Ataxia Treatments
8. OptiNose Receives Grant to Fund Nose-to-Brain Research in Autism Spectrum Disorders
9. Easy on the Stomach: ALCAT Worldwide Sponsors Successful Conference on Gut, Brain & Autoimmune Disorders
10. Elbit Imaging Ltd. Announces InSightecs ExAblate Neuro System Awarded European CE Mark for Non-invasive Treatment of Neurological Disorders in the Brain
11. Isis Pharmaceuticals Reports Positive Phase 1 Data On Three Drugs In Development To Treat Metabolic Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... 2017  ivWatch LLC, a medical device company focused ... therapy, is pleased to announce it was the Bronze ... Supplies and Equipment at the 2017 Medical Design Excellence ... industry. The award was presented by Medical Device and ... in New York during MD&M ...
(Date:6/11/2017)... 10, 2017  Eli Lilly and Company (NYSE: ... 3 studies of galcanezumab, an investigational treatment for the ... on several key secondary endpoints for galcanezumab compared to ... studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today ... in Boston . ...
(Date:6/8/2017)... LOS ANGELES , June 8, 2017   Responding ... prescription drug oversight and the death of singer Chris ... Commission on Human Rights International offers a free online ...  to better educate consumers and families about psychotropic drug risks. ... Heath Ledger , who died from an accidental overdose, has ...
Breaking Medicine Technology:
(Date:6/28/2017)... ... 28, 2017 , ... Quorum Health announced that Robert A. Vento has been ... John Maher was promoted to COO of QHR. , A national search ... president and CEO in December 2016. , “I’m pleased to announce ...
(Date:6/28/2017)... ... ... Drs. Steven Crandall, Karen Johnson and Kathy Lopez are now accepting new ... PA, without a referral. The doctors address jaw pain and other symptoms ... facial muscles that support it. , Jaw pain can be debilitating, and when ...
(Date:6/28/2017)... ... ... remote control has seen the never-ending twists on the house flipping show genre. The shows ... time. But what about the buyers of the flipper's flip. , Here is ... An email recently sent to Gary Case said, “Just closed on a home on ...
(Date:6/28/2017)... ... June 28, 2017 , ... The Wharton ... for mid-market executives as a kick-off to the fifth annual CEO Connection Mid-Market ... on the University of Pennsylvania campus, followed by the two-day convention, which will ...
(Date:6/28/2017)... Vancouver, British Columbia (PRWEB) , ... June 28, ... ... (OTCQB: CNZCF) (FSE: ZEON) is pleased to announce that a two year study ... using the Company's Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. ...
Breaking Medicine News(10 mins):